Clinical trials: AD
Alzheimer's Disease
Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients
The purpose of this Phase IIa study is to determine whether the AD Immunotherapeutic Vaccine (UB-311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in mild AD patients.
- Trial name
- NCT02551809
- Testing
- UB-311
- Where
- 4 sites in Taiwan
- Volunteers
- 43 people
- Sponsor
- United Neuroscience Ltd.
Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent participants.
- Trial name
- ROCKET-ASTRO (NCT05704738)
- Testing
- Rocatinlimab
- Where
- 246 sites in United States, Belgium and 20 more
- Volunteers
- 532 people
- Sponsor
- Amgen
Alzheimer Disease
Epidemiology and Biomarker Study in Alzheimer's Disease
Study AACU determines rates of cognitive worsening in participants within elevated and not elevated plasma P-tau217 cohorts. Participation in AACU will last approximately 7 years.
- Trial name
- ANCHOR-AD (NCT07142954)
- Testing
- P-tau217 Test
- Where
- 4 sites in United States, Japan
- Volunteers
- 3,400 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis (AD), Eczema
Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis
This is a Phase 2a efficacy and safety study of EVO301 for the treatment of adults with atopic dermatitis.
- Conditions
- Atopic Dermatitis (AD), Eczema, Eczema Atopic Dermatitis
- Trial name
- NCT06723405
- Testing
- EVO301
- Where
- 12 sites in Australia, New Zealand
- Volunteers
- 71 people
- Sponsor
- Evommune, Inc.
Alzheimer Disease (AD), Frontotemporal Lobar Degeneration
ADDIA Proof-of-Performance Clinical Study
The objective of the ADDIA clinical Proof-of-Performance study is to validate the performance of ADDIA' blood biomarkers for diagnosis of Alzheimer's disease (AD).
- Conditions
- Alzheimer Disease (AD), Frontotemporal Lobar Degeneration, Dementia with Lewy Bodies (DLB), Parkinson Disease Dementia (PDD)
- Trial name
- ADDIA (NCT03030586)
- Testing
- volumetric MRI
- Where
- 13 sites in Belgium, France and 3 more
- Volunteers
- 821 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Dermatitis, Atopic, Dermatitis
Abrocitinib Taiwan Treatment Pattern and Real World Study in ATopiC Dermatitis (ATTRACT Registry)
This study is to describe the real-world treatment patterns and clinical outcomes in moderate-to-severe AD patients receiving abrocitinib over a 12-month observation period, and to describe patient demographic and baseline…
- Conditions
- Dermatitis, Atopic, Dermatitis, Eczema, Skin Diseases
- Trial name
- ATTRACT (NCT06353087)
- Where
- 8 sites in Taiwan
- Volunteers
- 41 people
- Sponsor
- Pfizer
AD
Safety and Pharmacokinetic of Donepezil Pamoate in Healthy Subjects
The objective of this study is to evaluate the safety and pharmacokinetic profiles of HHT201 in healthy subjects.
- Trial name
- NCT03932916
- Testing
- Donepezil Pamoate for Injection 17mg, Donepezil Pamoate for Injection 34mg, Donepezil Hydrochloride 5mg
- Where
- China
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Shanghai Synergy Pharmaceutical Sciences Co., Ltd.
Dementia, Dementia Alzheimer Type
Plans4Care: Personalized Dementia Care on Demand
The Plans4Care study is a research study funded by the National Institute on Aging (Grant# R44AG084365). The Plans4Care app is designed to help family caregivers address over 90 common care challenges such as behavioral symptoms…
- Conditions
- Dementia, Dementia Alzheimer Type, Alzheimer Dementia (AD), Memory Loss
- Trial name
- NCT07115251
- Testing
- Plans4Care
- Volunteers
- 160 people
- Sponsor
- Plans4Care Inc
Alzheimer's Disease
SLS-005 (Trehalose Injection) in the Treatment of Alzheimer's Disease
An open-label, proof-of-concept study to evaluate the safety and treatment effects of SLS-005 in Participants with Alzheimer's Disease (AD) treated once or twice weekly for 52 weeks.
- Trial name
- [STRIVE-AD] (NCT05332678)
- Testing
- SLS-005 - Once Weekly, SLS-005 - Twice Weekly
- Where
- 3 sites in Australia
- Sponsor
- Seelos Therapeutics, Inc.
Alzheimer Disease (AD)
A Study Evaluating the Efficiency and Safety for the VGuard Device in Alzheimer's Disease.
The project will allow the assessment of the safety and clinical effectiveness of the device for the treatment of cognitive impairment at Alzheimer\'s diease.
- Trial name
- CogniGuard (NCT06620640)
- Testing
- Intervention will most probably modify activity of neuron networks in specific brain areas responsible for cognitive functions, especially memory consolidation.
- Where
- Poland
- Volunteers
- 105 people
- Sponsor
- Neuromedical Sp. z o.o.
Alzheimer's Disease, Sleep Disorder
Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor
The aim of this exploratory randomized, placebo controlled study is to evaluate the efficacy of Circadin® 2mg in patients with mild to moderate Alzheimer Disease (AD) treated with the acetylcholinesterase (AChE) inhibitor.
- Trial name
- NCT00940589
- Testing
- Circadin
- Where
- 6 sites in United States, Israel and 1 more
- Volunteers
- 73 people
- Sponsor
- Neurim Pharmaceuticals Ltd.
Alzheimers Disease
A Phase 0, Open Label, Multi-Center, Exploratory and Safety Study of [F-18]T808
[F-18]T808 is being developed as a diagnostic radiopharmaceutical for PET imaging of the human brain.
- Trial name
- T808 (NCT01723488)
- Testing
- [F18] T808
- Where
- 2 sites in United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers
This proof-of-mechanism clinical trial study will test the efficacy and safety of thiethylperazine (TEP) in subjects with early onset of Alzheimer's Disease (AD).
- Trial name
- drainAD (NCT03417986)
- Testing
- TEP
- Where
- 2 sites in Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Immungenetics AG
Alzheimer Disease
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
The main purpose of the study was to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with AD.
- Trial name
- NCT04339413
- Testing
- Gantenerumab
- Where
- 56 sites in United States, Argentina and 15 more
- Volunteers
- 116 people
- Sponsor
- Hoffmann-La Roche
Mild Cognitive Impairment, Dementia
An Imaging Study to Investigate the Distribution of GSK239512 in the Brain.
GSK239512 is being developed for the treatment of symptoms of cognitive impairment in many diseases. GSK239512 is a drug that binds to the Histamine 3 receptor (a protein) in the brain (receptor occupancy).
- Trial name
- NCT00474513
- Testing
- GSK239512
- Where
- Canada
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alzheimer s Disease
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study
- Trial name
- NCT07764146
- Testing
- VY1706 Low dose, VY1706 Mid dose, VY1706 High Dose
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Voyager Therapeutics
Dermatitis, Atopic
A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants With Moderate to Severe Atopic Dermatitis
The purpose of this first-in-human (FIH) study is to assess the safety and tolerability, pharmacokinetics (PK), immunogenicity (IG) and pharmacodynamics (PD) of DCY636.
- Trial name
- NCT07604324
- Testing
- DCY636
- Where
- Japan
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Moderate-to-severe Atopic Dermatitis
Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD)
This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of subcutaneously CM310 in moderate-severe AD…
- Trial name
- NCT04893941
- Testing
- CM310
- Where
- 7 sites in China
- Volunteers
- 39 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis (AD)
A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)
This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.
- Trial name
- NCT07544862
- Testing
- Stapokibart
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chengdu Kangnuoxing Biopharma,Inc.
Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI)
Study to Detect Dendritic Cell Recruitment in Human Retina
The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of…
- Conditions
- Dry Age Related Macular Degeneration, Mild Cognitive Impairment (MCI), Alzheimer Disease
- Trial name
- ICG-002 (NCT06872658)
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- MindImmune Therapeutics, Inc.